SLC9A1 and stroke disorder: In the current study, the blockade of NHE1 protein activity with HOE642 (Cariporide) or Rimeporide at 24 h post-stroke displayed no acute neuroprotection but reduced inflammatory responses, enhanced white matter repair, and improved motor and cognitive function recovery up to 1 month after stroke.